SCT raises additional capital from angel investors to finance dog trials

Written by Travis Manning

SCT raised an additional $1.9M from angel investors. This is the third seed-stage round of funding for SCT. To date, the company has raised over $7.5M towards the development of its novel technologies for the treatment of insulin-dependent diabetes mellitus. The capital raised from this round will be used towards upcoming clinical trials in dog patients.

Travis Manning https://www.symbiocelltech.com
Previous

SymbioCellTech recieves FDA approval to conduct pilot studies in pet dogs
Next

SCT Submits FDA Application For Dog Trials